Clinical Chemistry AACC Online Job Center
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Clinical Chemistry 20: 454-464, 1974;
This Article
Right arrow Full Text (PDF)
Right arrow A correction has been published
Right arrow A correction has been published
Right arrow Submit an electronic Letter to
the Editor about this paper
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Rej, R.
Right arrow Articles by Vanderlinde, R. E.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Rej, R.
Right arrow Articles by Vanderlinde, R. E.

Clinical Chemistry, Vol 20, 454-464, Copyright © 1974 by the American Association for Clinical Chemistry

Assay of Aspartate Aminotransferase Activity: Effects of Serum and Serum Proteins on Oxalacetate Decarboxylation and Dialysis

Robert Rej 1 and Raymond E. Vanderlinde 1

1 Division of Laboratories and Research, New York State Department of Health, Albany, N. Y. 12201.

Effects of serum and protein on assays measuring aspartate aminotransferase (L-aspartate:2-oxoglutarate aminotransferase, EC 2.6.1.1) were examined. Increasing amounts of normal human serum or human serum albumin in samples with fixed amounts of purified enzyme decrease absorbance values and thus distort the results obtained in an assay in which diazonium-salt chromogenic reagent is used. Serum also directly accelerates disappearance of oxalacetate from an incubation medium similar to that of the enzyme assay studied. Protein accelerates spontaneous decarboxylation of oxalacetate to pyruvate, preventing its quantitation in assays specific for oxalacetate. Primary amine groups of protein are evidently involved, because acylated albumin does not accelerate decarboxylation. This effect is not attributable to metal ions in serum and is not significant in procedures involving use of the less specific dinitrophenylhydrazine, which measure the decarboxylation product, pyruvate. Continuous kinetic assays of aspartate aminotransferase activity, in which oxalacetate is not allowed to accumulate, are unaffected by protein concentration. Fivefold dilution of patients’ sera with physiological saline results in activities that are artifactually high by 56% in affected assays. Varying oxalacetate decarboxylation is also a source of error in the estimation of malate dehydrogenase (L-malate:NAD oxidoreductase; EC 1.1.1.37) activity in body fluids. Protein increases the values obtained by automated procedures requiring dialysis by increasing the amount of oxalacetate diffusing into the chromogenic flow stream. A solution of albumin, about 6 g/dl, is suggested as a dilution fluid for use with the affected assays.


Key Words: AutoAnalyzer methods • Acta II • Kintrac VII • effects of serum vs. those of albumin • intermethod comparisons • analytical variation, source of • suitable diluent for specimens • standardization of enzyme assays

Submitted on December 31, 1973
Accepted on January 29, 1974






HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 1974 by the American Association for Clinical Chemistry.